Colgate-Palmolive Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CL research report →
Range $95 – $112
Price Chart
About the company
Operating globally, Colgate-Palmolive Company and its affiliated entities are engaged in the production and distribution of a diverse range of consumer goods. Its operations are structured into two primary divisions: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care division encompasses a broad array of offerings, spanning oral hygiene (e.
- CEO
- Noel R. Wallace
- IPO
- 1973
- Employees
- 33,600
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on CL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $78.47B
- P/E
- 38.70
- Fwd P/E
- 25.21
- PEG
- -1.36
- P/S
- 3.72
- P/B
- 276.35
- EV/EBITDA
- 22.11
- Div Yield
- 2.12%
- Gross Margin
- 60.61%
- Op Margin
- 20.38%
- Net Margin
- 9.65%
- ROE
- 1135.82%
- ROIC
- 29.87%
Latest fiscal year · YoY change
- Revenue
- $20.38B+1.4%
- Gross Profit
- $12.25B+1.2%
- Op Income
- $3.31B
- Net Income
- $2.13B-26.2%
- EPS
- $2.64-25.2%
- OCF Growth
- +2.2%
- FCF Growth
- +2.5%
- 52W High
- $101.81
- 52W Low
- $75.96
- 50D MA
- $91.83
- 200D MA
- $90.45
- Beta
- 0.31
- RSI (14)
- 58
- Avg Volume
- 5.07M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Colgate-Palmolive said Q3 2026 delivered broad-based organic growth, gross margin expansion, and better-than-expected EPS despite a stubborn cost and logistics backdrop.· October 30, 2026
- Organic sales growth was broad-based across all four categories and four of five divisions, led by emerging markets and strong Hill’s performance.
- Base business EPS came in ahead of expectations even as advertising spend increased.
- Gross margin expanded, supported by pricing, productivity programs, and premium innovation, while raw materials and logistics remained headwinds.
- Management raised full-year gross margin guidance and said 2026 cost projections are largely locked in, though pressure is expected to stay elevated into Q4 and early 2027.
- U.S. toothpaste remains a turnaround, with early share improvement but still sluggish categories and a focus on premium innovation, AI, and a revamped go-to-market model.
The company did not state consolidated revenue, EPS, or gross margin percentages in the transcript, but management said organic sales growth was positive across all four categories and four of five divisions, base business EPS came in ahead of expectations, free cash flow was up 7%, and $2.2 billion was returned to shareholders year-to-date. Emerging markets were up mid-single digits, Hill’s had a very strong quarter, Latin America was up 6% with volume up 3.9% and 2% pricing, and Hill’s reported top line of 6.5% ex-private label with gross margin up 170 basis points. Stan Sutula said material cost was roughly a 300 basis point headwind year-to-date, funding-the-growth offset over 290 basis points, pricing contributed 80 basis points, and mix added about 20 basis points. The company raised full-year gross profit margin guidance from roughly flat to up on a year-on-year basis, and said Q4 commodity costs are largely locked in, with logistics costs expected to be the highest of the year. Management said 2026 cost inflation remains roughly in the original $300± million range.
Noel Wallace’s tone was confident but cautious: he emphasized that the company is executing well in a volatile global environment, with organic growth, margin expansion, and strong cash flow all coming through despite elevated costs. Strategically, he leaned heavily on pricing discipline, premium innovation, omni-channel demand generation, AI-enabled execution, and productivity programs such as funding-the-growth and SGPP. He also repeatedly framed the U.S. as a work in progress, saying the turnaround will depend on better premium innovation, stronger advertising effectiveness, and a more connected go-to-market model.
Stan Sutula focused on how the company is offsetting cost pressure through productivity and pricing. He said material costs were roughly a 300 basis point headwind year-to-date, funding-the-growth offset over 290 basis points, pricing added 80 basis points, and mix added about 20 basis points; he also said raw and pack costs in Q3 were significant headwinds, especially resins, petrochemicals, pulp, and paper. He said commodities are largely locked in for Q4, but logistics costs are the highest of the year and should stay elevated into next year. He also said SGPP is helping drive overhead efficiency, with the program running through the end of 2028, and noted total-company EBIT margins were up slightly year over year.
Analysts focused on how management is thinking about 2027, especially with elevated costs, rising logistics pressure, and whether pricing will need to increase further. Management declined to give 2027 guidance, but said cost pressure should peak in Q4 and remain elevated into early 2027, with pricing, productivity, and premium innovation used to offset it. Questions also centered on the U.S. toothpaste turnaround, Hill’s sustainability, and whether there was any destocking in North America; management said there was no meaningful destocking and that the U.S. plan hinges on premium bundles, more targeted advertising, and a redesigned commercial model. Several analysts pressed on Hill’s momentum and margins, and management answered that growth is concentrated in cat, wet, and therapeutic segments, with Fresh still a disciplined long-term rollout.
The call showed strong execution across emerging markets, Europe, and Hill’s, with management repeatedly pointing to market share gains, premium innovation, and solid volume growth. Free cash flow was up 7%, shareholder returns were $2.2 billion year-to-date, and management said it is getting pricing into the P&L quickly enough to protect margins even in a tough cost environment.
Management said the cost environment remains stubborn and could get worse before it gets better, with tariffs peaking in Q4, logistics costs still rising, and commodity pressure expected to stay elevated into 2027. The U.S. remains a turnaround story, Mexico faced a difficult consumer and retailer backdrop, and China categories were still challenged by soft brick-and-mortar demand and a shift to online channels.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.9%
- Shares Outstanding
- 794.92M
- Float Shares
- 746.52M
of shares held by institutions
2,085 13F filers
Buy/sell ratio 0.75. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CL, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 25, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Aug 27, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Aug 31, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Sep 2, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Aug 19, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Buy | Sep 23, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Sep 23, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jun 2, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 7, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Sep 11, 25 | Filing → |
| Richard Ray LarsenHouse · WA02 | Sell | Oct 6, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 83.95M | ▲ 1.03M |
| Blackrock, Inc. | 69.99M | ▲ 75.61K |
| Vanguard Capital Management LLC | 52.14M | ▼ 106.49K |
| State Street Corp | 46.62M | ▼ 399.68K |
| Vanguard Portfolio Management LLC | 34.95M | ▲ 10.93M |
| Price T Rowe Associates Inc | 27.91M | ▼ 5.82M |
| Geode Capital Management, LLC | 23.46M | ▲ 320.62K |
| Morgan Stanley | 22.15M | ▲ 75.30K |
| Bank Of New York Mellon Corp | 13.32M | ▼ 211.03K |
| Deutsche Bank AG\ | 11.54M | ▼ 210.97K |
| Acadian Asset Management LLC | 11.21M | ▲ 2.11M |
| Fmr LLC | 9.71M | ▲ 729.94K |
Held by 1,879 ETFs
Biggest fund positions in CL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Malcolm Gregory | sell | 4,100 |
| Nov 5, 26 | NORRINGTON LORRIE M | other | 4,170 |
| Nov 5, 26 | NORRINGTON LORRIE M | sell | 4,170 |
| Nov 5, 26 | NORRINGTON LORRIE M | other | 4,170 |
| Nov 5, 26 | Wallace Noel R. | sell | 20,000 |
| Nov 4, 26 | Tsourapas Panagiotis | other | 19,938 |
| Nov 4, 26 | Tsourapas Panagiotis | sell | 19,938 |
| Nov 4, 26 | Tsourapas Panagiotis | other | 19,938 |
| Nov 4, 26 | Hazlin John | other | 23,376 |
| Nov 4, 26 | Hazlin John | sell | 23,376 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CL coverage
Recent articles, reports, and earnings notes.

Inside the vVARDIS Holding AG IPO: Growth, Risks, and Verdict
vVARDIS Holding AG Class A is expected to list on the NYSE on 2026-11-13 in a priced IPO at $21.00 to $24.00 per share. The Swiss oral-health company is coming public with rapid revenue growth, but it is still loss-making and heavily dependent on U.S. adoption of its core product.

Inside Our Top Dividend Kings Stock Picks for September 2026
Our seven-stock Dividend Kings countdown spans industrials, healthcare, beverages, restaurants and household staples, with four lower-ranked names available in the free portion.
Want a deeper read on CL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Colgate-Palmolive vs. lululemon athletica: Which Consumer Goods Stock Is a Better Buy for 2027?
fool.com · Nov 20
Colgate Has Raised Its Dividend for 63 Years. These 3 Staples Stocks Offer Income
247wallst.com · Nov 19
2 Unstoppable Dividend Stocks I'd Buy With $1,000 Before the End of November
fool.com · Nov 18
Colgate-Palmolive Webcasts Fireside Chat at the Morgan Stanley Global Consumer & Retail Conference
businesswire.com · Nov 18
Colgate-Palmolive vs. Kimberly-Clark: Which Household Name Deserves Your Investment Dollars?
fool.com · Nov 15
Celsius vs. Colgate-Palmolive: Which Consumer Goods Stock Is a Better Buy for 2027?
fool.com · Nov 13
What If the Fed Doubles the Rate Hike in December? These 5 Dividend Stocks Could Prosper
247wallst.com · Nov 13
Procter & Gamble Has Raised Its Dividend for 70 Straight Years. Where’s the Price Target Now?
247wallst.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.